Overview

GCC19CART for Patients With Metastatic Colorectal Cancer

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Innovative Cellular Therapeutics Inc.